Navigation Links
ViroPharma Announces Securities Repurchase Program
Date:3/9/2011

EXTON, Pa., March 9, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company's Board of Directors has authorized the use of up to $150 million to repurchase shares of its common stock and/or its 2% Senior Convertible Notes due 2017.

Purchases may be made by means of open market transactions, block transactions, privately negotiated purchase transactions or other techniques from time to time, as determined by ViroPharma's management, and in accordance with the requirements of the Securities and Exchange Commission. As of December 31, 2010, ViroPharma had 78,141,491 shares of common stock issued and outstanding.

The sources of cash for this repurchase program are a combination of our cash, cash equivalents and short term investments on our balance sheet and our anticipated cash flows from operations.  ViroPharma produced cash flows of $194 million for the year 2010.

"We are committed to enhancing shareholder value through a variety of efforts," said Charles Rowland, ViroPharma's chief financial officer.  "To that end, today's announcement demonstrates our confidence in the future prospects of our existing business and our ongoing financial strength, which will continue to provide us the ability to pursue additional business development opportunities."

About ViroPharma IncorporatedViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin® (Vancomycin Hydrochloride Capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile infection.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward Looking StatementsCertain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. There can be no assurance that we will be successful in enhancing shareholder value, that the future prospects of our existing business will derive ongoing financial strength, or that we will be successful in completing future business development transactions. These factors, and other factors, including, but not limited to those described in our annual report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release are made as of the date hereof and may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. These forward looking statements should not be relied upon as representing our assessments as of any date subsequent to the date of this press release. ViroPharma Incorporated Contacts:Robert A. DoodyAssistant Director, Investor RelationsPhone (610) 321-6290
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma to Participate in Two March Healthcare Conferences
2. ViroPharma to Release 2010 Fourth Quarter and Full Year Financial Results on February 24, 2011
3. ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
4. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
5. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
6. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
7. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
8. ViroPharma To Participate in Two September Healthcare Investor Conferences
9. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
10. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
11. ViroPharma to Participate in Two June Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... LONDON , May 27, 2016 ... an innovative biopharma company focused on the highly ... built a substantial pipeline of potential first-in-class or ... which are in development with strategic partners. HCM,s ... the fast-growing domestic market. We expect progress of ...
(Date:5/26/2016)... -- According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - ... valued at US$ 5.89 Bn in 2014 and is anticipated ... 2023 to reach US$ 7.99 Bn in 2023. ... free drug delivery devices and the market is estimated based ...
(Date:5/26/2016)... , May 26, 2016 ... has matured into an essential life science tool for ... development applications. BCC Research reveals in its new report ... second growth phase, one powered by a range of ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... More than a third of American adults ... that bariatric surgery has received increased attention in recent years, as an article ... comes to weight loss, most people are familiar with the basic requirements of maintaining ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and ... to shed lights on the variety of topics detailing why we appreciate nurses in ... why this career has gone from being in a major recession to one of ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response to ... who are unaware of the plight of aphasia. In collaboration with the American ... Awareness” campaign. , The link between stroke and aphasia is relatively unknown, but ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... her award on May 18 at the university’s Student Leadership Awards ceremony. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. Inc ... honored with a 2016 When Work Works Award for its use of effective workplace ... national When Work Works project administered by the Families and Work Institute (FWI) and ...
Breaking Medicine News(10 mins):